Adam C. Kessel

Adam C. Kessel

Auto-generated profile, based on publicly available information

Adam C. Kessel

Department of Radiation Oncology Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
FTFadi Taza
Fadi Taza
AHAlbert E. Holler
Albert E. Holler
WFWei Fu
Wei Fu
HWHao Wang
Hao Wang
NANabil Adra
Nabil Adra
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
PURPOSE: Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration–approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/ 2 mutations, but the relative efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC is understudied.METHODS: We conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with BRCA1/ 2-altered mCRPC who were treated with PARP inhibitors. The primary efficacy end point was the prostate-specific antigen (PSA) response (≥ 50% PSA decline) rate. Secondary end points were PSA progression-free survival (PSA-PFS), clinical or radiographic PFS, and overall survival. We compared clinical outcomes, and other genomic characteristics, among BRCA1- versus BRCA2-altered mCRPC.RESULTS: A total of 123 patients (13 BRCA1 and 110 BRCA2) were included. PARP inhibitors used were olaparib (n = 116), rucaparib (n = 3), talazoparib (n = 2), and veliparib (n = 2). At diagnosis, 72% of patients had Gleason 8-10 disease. BRCA1 patients were more likely to have metastatic disease at presentation (69% v 37%; P = .04). Age, baseline PSA, metastatic distribution, and types of previous systemic therapies were similar between groups. There were equal proportions of germline mutations (51% v 46%; P = .78) in both groups. BRCA1 patients had more monoallelic (56% v 41%; P = .49) and concurrent TP53 (55% v 36%; P = .32) mutations. PSA50responses in BRCA1- versus BRCA2-altered patients were 23% versus 63%, respectively ( P = .01). BRCA2 patients achieved longer PSA-PFS (HR, 1.94; 95% CI, 0.92 to 4.09; P = .08), PFS (HR, 2.08; 95% CI, 0.99 to 4.40; P = .05), and overall survival (HR, 3.01; 95% CI, 1.32 to 6.83; P = .008). Biallelic (compared with monoallelic) mutations, truncating (compared with missense) mutations, and absence of a concurrent TP53 mutation were associated with PARP inhibitor sensitivity.CONCLUSION: PARP inhibitor efficacy is diminished in BRCA1- versus BRCA2-altered mCRPC. This is not due to an imbalance in germline mutations but might be related to more monoallelic mutations and/or concurrent TP53 alterations in the BRCA1 group.

13 August 2022 in Brachytherapy
Verified
Journal Article
Closed access
RHRyan J. Hutten
Ryan J. Hutten
JFJordan B. Fenlon
Jordan B. Fenlon
AKAdam C. Kessel
Adam C. Kessel
KSKrystal M. Straessler
Krystal M. Straessler
YHY. Jessica Huang
Y. Jessica Huang
LBLindsay M. Burt
Lindsay M. Burt

20 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Umang SwamiUmang Swami
Umang Swami
BCBeverly Chigarira
Beverly Chigarira
NSNICOLAS SAYEGH
NICOLAS SAYEGH
TMTaylor Ryan McFarland
Taylor Ryan McFarland
NTNishita Tripathi
Nishita Tripathi
NANeeraj Agarwal
Neeraj Agarwal
133 Background: In the PEACE-1 trial (Fizazi, ESMO 2021), in pts with dn-hv-mCSPC, the addition of abiraterone to ADT + docetaxel (triplet therapy arm) resulted in a median OS of 61 months (OS on ADT + docetaxel arm was 42 months). However, independent contribution of docetaxel to efficacy of ADT + abiraterone in the triplet therapy arm of PEACE-1 trial is not clear. Furthermore, the efficacy of an novel hormonal therapy (NHT) specifically in dn-hv-mCSPC population has not been reported (LATITUDE trial’s eligibility did not include volume status). Herein, our objective was to assess PFS and OS in a cohort of dn-hv-mCSPC pts undergoing intensified ADT with either NHT (i.e. novel androgen receptor or androgen synthesis inhibitors) or docetaxel. Methods: In this IRB-approved study, patient-level data were collected retrospectively. Eligibility: presence of dn-hv-mCSPC (hv per CHAARTED criteria) undergoing intensified ADT with either NHT or docetaxel started within 3 months of diagnosis. Study endpoints: PFS was calculated per PCWG-2 - defined PSA progression or radiographic progression or clinical progression whichever occurred first; OS was defined as start of therapy to date of death or censored at last follow-up. A multivariate analysis using the Cox proportional hazards (Cox-ph) model was used; the relationship between treatment intensification with both PFS and OS was assessed and adjusted for age at diagnosis, Gleason score, presence of visceral metastases, and PSA at baseline. Results: 85 pts with dn-hv-mCSPC were included: 45 received ADT + NHT; 40 received ADT + docetaxel. In the NHT vs docetaxel arms: median PFS were 23 vs 14 months; and median OS were 63 vs 36 months respectively. See the table for Cox-ph and adjusted co-variate results. Conclusions: We for the first-time report the real-world survival outcomes with ADT + NHT specifically in pts with dn-hv-mCSPC. In addition, in these hypothesis-generating data, the OS of pts with dn-hv-mCSPC undergoing ADT + NHT or ADT + docetaxel were similar to those in the triplet therapy arm or ADT + docetaxel arm of PEACE-1 trial respectively. A randomized trial in pts with dn-hv-mCSPC comparing ADT + NHT vs triplet therapy may better characterize the benefit of the docetaxel component in the triplet therapy.[Table: see text]

20 May 2026 in Cancer
Verified
Journal Article
Closed access
AKAdam C. Kessel
Adam C. Kessel
HKHayeon Kim
Hayeon Kim
PBPaul Brown
Paul Brown
ELEric J. Lehrer
Eric J. Lehrer
NLNadia N. Laack
Nadia N. Laack
RKRoman Oleksander Kowalchuk
Roman Oleksander Kowalchuk

20 October 2022 in International Journal of Cancer Care and Delivery
Verified
Journal Article
Open access
PDF file
Umang SwamiUmang Swami
Umang Swami
BCBeverly Chigarira
Beverly Chigarira
NSNICOLAS SAYEGH
NICOLAS SAYEGH
TMTaylor Ryan McFarland
Taylor Ryan McFarland
NTNishita Tripathi
Nishita Tripathi
NANeeraj Agarwal
Neeraj Agarwal
By Umang Swami, Beverly Chigarira & 13 more. A study on patients with prostate cancer

28 July 2026 in British Journal of Haematology
Verified
Journal Article
Closed access
AKAdam C. Kessel
Adam C. Kessel
JBJessica F. Burlile
Jessica F. Burlile
KFKelsey Freschette
Kelsey Freschette
WTW. Oliver Tobin
W. Oliver Tobin
GGGaurav Goyal
Gaurav Goyal
WBWilliam G. Breen
William G. Breen